Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio

ALS Data For Verdiperstat Expected In 2022

The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.

A Businessperson Stopping Colorful Dominoes From Falling On Desk — Late-stage failures have stopped Biohaven from achieving success outside of its migraine pipeline • Source: Alamy

Biohaven Pharmaceutical Holding Company Ltd. wants to be a player in neurological and neuropsychiatric diseases, but the company has yet to report a clinical trial success outside of its CGRP inhibitor platform for the treatment of migraine. The most recent setback, disclosed on 27 September, is the failure of the myeloperoxidase (MPO) enzyme inhibitor verdiperstat in multiple system atrophy (MSA) to differentiate from placebo on the primary and secondary endpoints in a Phase III trial.

Analysts consistently viewed the setback as a minor event for Biohaven since the company’s valuation is largely based on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

20 Jun 2025

• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

19 Jun 2025

• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.